GeneDx Holdings Corp. (WGS) income statement
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3049% above fair value
$51.96+4.67 (+9.88%)
Close on Nov 18, 2026Market cap $1.55BP/E –Yield –
GeneDx Holdings Corp. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 69.4%
- Operating margin
- -20.3%
- Net margin
- -23.4%
- Return on equity, FY2025
- -7.6%
Financial strength
- Current ratio
- 3.30
- Debt to equity
- 0.40
- Debt to assets
- 20.1%
- Cash to current liabilities
- 80.8%
Valuation
- P/E ratio
- –
- Price to sales
- 3.41
- Price to book
- 6.34
- Dividend yield
- –
See a number that looks wrong?